CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,408 enrolled
Drug / intervention
Cat-PAD +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01620762
NCT01620762Phase 3Completed
CompareCT.gov

A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects

Circassia Limited·interventional·Posted Jun 15, 2012·Updated Jun 15, 2018

In Brief

A Phase 3 clinical trial evaluating Cat-PAD and Placebo for Rhinoconjunctivitis. Completed, enrolled 1,408 participants across 118 sites in 9 countries.

Detailed Summary

The purpose of this study is to compare the treatment effect of two treatment regimens of Cat-PAD vs placebo and to evaluates the treatment effect of Cat-PAD on symptoms, rescue medication usage and Quality of Life.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRhinoconjunctivitis
CountriesBelgium, Canada, Czechia, Germany, Hungary, Poland, Russia, Slovakia, United States
CollaboratorsinVentiv Health Clinical, Pharm-Olam International

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 15, 2012
Enrollment StartOct 1, 2012
Primary CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 14.0 years ago

Interventions

Cat-PADdrug

1 dose every 4 weeks

Placebodrug

1 dose every 4 weeks